Ticagrelor plus aspirin versus clopidogrel plus aspirin for platelet reactivity in patients with minor stroke or transient ischaemic attack: open label, blinded endpoint, randomised controlled phase II trial

OBJECTIVE: To test the hypothesis that ticagrelor plus aspirin is safe and superior to clopidogrel plus aspirin for reducing high platelet reactivity at 90 days and stroke recurrence in patients with minor stroke or transient ischaemic attack, particularly in carriers of the CYP2C19 loss-of-function...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:BMJ
Päätekijät: Wang, Yilong, Chen, Weiqi, Lin, Yi, Meng, Xia, Chen, Guohua, Wang, Zhimin, Wu, Jialing, Wang, Dali, Li, Jianhua, Cao, Yibin, Xu, Yuming, Zhang, Guohua, Li, Xiaobo, Pan, Yuesong, Li, Hao, Zhao, Xingquan, Liu, Liping, Lin, Jinxi, Dong, Kehui, Jing, Jing, Johnston, S Claiborne, Wang, David, Wang, Yongjun
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: BMJ Publishing Group Ltd. 2019
Aiheet:
Research
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6549283/
https://ncbi.nlm.nih.gov/pubmed/31171523
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bmj.l2211
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia